Article
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Blood - 23 Dec 2010
Wang Xiaoli, Zhang Wei, Tripodi Joseph, Lu Min, Xu Mingjiang, Najfeld Vesna, Li Yan, Hoffman Ronald
Abstract excerpt
Because primary myelofibrosis (PMF) originates at the level of the pluripotent hematopoietic stem cell (HSC), we examined the effects of various therapeutic agents on the in vitro and in vivo behavior of PMF CD34(+) cells. Treatment of PMF CD34(+) cells with chromatin-modifying agents (CMAs) but not hydroxyurea, Janus kinase 2 (JAK2) inhibitors, or low doses of interferon-α led to the generation of greater...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.